| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Adaptimmune Therapeutics plc (NASDAQ: ADAP)
ADAP Technical Analysis
5
| As on 9th Jun 2023 ADAP STOCK Price closed @ 0.99 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.10 & Strong Sell for SHORT-TERM with Stoploss of 3.16 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ADAPSTOCK Price
| Open | 1.02 | Change | Price | % |
| High | 1.04 | 1 Day | -0.02 | -1.98 |
| Low | 0.96 | 1 Week | -0.12 | -10.81 |
| Close | 0.99 | 1 Month | -0.33 | -25.00 |
| Volume | 1024127 | 1 Year | -2.91 | -74.62 |
| 52 Week High 4.11 | 52 Week Low 1.02 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ADAP Daily Charts |
ADAP Intraday Charts |
Whats New @ Bazaartrend |
ADAP Free Analysis |
|
|
ADAP Important Levels Intraday
| RESISTANCE | 1.14 |
| RESISTANCE | 1.09 |
| RESISTANCE | 1.06 |
| RESISTANCE | 1.03 |
| SUPPORT | 0.95 |
| SUPPORT | 0.92 |
| SUPPORT | 0.89 |
| SUPPORT | 0.84 |
ADAP Forecast April 2024
| 4th UP Forecast | 3.48 |
| 3rd UP Forecast | 2.68 |
| 2nd UP Forecast | 2.19 |
| 1st UP Forecast | 1.69 |
| 1st DOWN Forecast | 0.29 |
| 2nd DOWN Forecast | -0.21 |
| 3rd DOWN Forecast | -0.7 |
| 4th DOWN Forecast | -1.5 |
ADAP Weekly Forecast
| 4th UP Forecast | 1.93 |
| 3rd UP Forecast | 1.63 |
| 2nd UP Forecast | 1.44 |
| 1st UP Forecast | 1.26 |
| 1st DOWN Forecast | 0.72 |
| 2nd DOWN Forecast | 0.54 |
| 3rd DOWN Forecast | 0.35 |
| 4th DOWN Forecast | 0.05 |
ADAP Forecast2024
| 4th UP Forecast | 7.18 |
| 3rd UP Forecast | 5.19 |
| 2nd UP Forecast | 3.97 |
| 1st UP Forecast | 2.74 |
| 1st DOWN Forecast | -0.76 |
| 2nd DOWN Forecast | -1.99 |
| 3rd DOWN Forecast | -3.21 |
| 4th DOWN Forecast | -5.2 |
Adaptimmune Therapeutics plc ( NASDAQ USA Symbol : ADAP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ADAP Business Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service